drugset / Trial / NCT01495013

A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus

NCT01495013

Phase 3 Completed 427 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this 20 week study is to show that glimepiride/atorvastatin fixed dose combination tablet is safe and as effective as atorvastatin + glimepiride combination taken as separate tablets, in improving glycaemic control (glycated haemoglobin, HbA1c) and cholesterol levels (Low-density lipoprotein, LDL) in diabetic subjects, who are inadequately controlled on a stable dose of metformin. Eight dose combinations will be included.

Timeline

Start
2011-12
Primary completion
2013-04
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 10 mg Oral
Comparator Atorvastatin Small molecule 20 mg Oral
Comparator Glimepiride Small molecule 1 mg Oral
Comparator Glimepiride Small molecule 2 mg Oral
Comparator Glimepiride Small molecule 3 mg Oral
Comparator Glimepiride Small molecule 4 mg Oral